Skip to NavigationSkip to content

Haslam

Storm brewing over Roche cancer drug price

Kadcyla packshot

The Breakthrough Breast Cancer charity and England’s drug pricing watchdog NICE have both attacked Roche for not lowering the price of its new breast cancer drug Kadcyla.

The drug has been knocked back by NICE today in its final draft guidance for patients with HER2-positive breast cancer that has spread to other parts of the body, cannot be surgically removed and has stopped responding to first-line treatment.

Researchers question ‘bias’ NICE on statins

Statins image

Doctors are warning that NICE’s desire to increase prescriptions of statins in England is based on pharma-funded research that ignores their potentially dangerous side effects.

Writing to both ministers and to the chairman of NICE – Professor David Haslam – senior British doctors argue that the draft advice was overly reliant on industry-sponsored trials, which ‘grossly underestimate adverse effects’, which can include increasing the ris

NICE chair: pharma must show how it prices drugs

Haslam image
Professor David Haslam (Credit: Financial Times Live)

The pharmaceutical industry must be willing to show the public how it prices its drugs - or face losing its trust.

This is according to the chairman of NICE Professor David Haslam, who tells Pharmafile that currently no one outside the boardroom of a pharma firm knows how it evaluates a drug’s worth.

“If we could have greater transparency about pricing, then a lot of problems could be bypassed - it’s not just that drugs are expensive and NICE says no, it’s about the cost-effectiveness of
these medicines. 

David Haslam confirmed as NICE chair

Published on: 18/12/12

David Haslam has been confirmed as chair of the National Institute for Health and Clinical Excellence.

Professor Haslam is currently the National Clinical adviser to the Care Quality Commission, chair of the NICE Evidence Accreditation Advisory Board and an expert member of the NHS National Quality Board. 

Haslam will head up NICE, currently a Special Health Authority which will become an Executive Non-Departmental Public Body from 1 April 2013 when it extends its remit to adults’ and children’s social care.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches